A drug-loaded implanted medical device (10) and a preparation method therefor. The drug-loaded implanted medical device (10) comprises a device body (100), a hydrophilic coating layer (200) loaded on the device body (100), and crystalline drug particles (300) loaded on the hydrophilic coating layer (200). The hydrophilic coating layer (200) comprises a graft polymer containing a photo-crosslinked group. The medical device (10) uses a hydrophilic coating layer (200) as a carrier, effectively avoiding the risk of embolism, encouraging the crystalline drug particles to fall off, and helping to achieve a target tissue concentration. The invention can also effectively increase the anchoring effect between the carrier and the device, and reduce toxicity.

A drug-loaded implanted medical device (10) and a preparation method therefor. The drug-loaded implanted medical device (10) comprises a device body (100), a hydrophilic coating layer (200) loaded on the device body (100), and crystalline drug particles (300) loaded on the hydrophilic coating layer (200). The hydrophilic coating layer (200) comprises a graft polymer containing a photo-crosslinked group. The medical device (10) uses a hydrophilic coating layer (200) as a carrier, effectively avoiding the risk of embolism, encouraging the crystalline drug particles to fall off, and helping to achieve a target tissue concentration. The invention can also effectively increase the anchoring effect between the carrier and the device, and reduce toxicity.

The present disclosure presents hydrogel compositions for use in the treatment of an ocular disorder (e.g., a retinal disease) and methods of treating an ocular disorder in a subject in need thereof with the hydrogel compositions. The hydrogel compositions can include hydroxyphenylpropionic acid (gelatin-HPA), hyaluronic acid-tyramine (HA-Tyr), a catalyzer (e.g., horseradish peroxidase (HRP)), a cell, a crosslinker (e.g., hydrogen peroxide), or any combination thereof. The methods include administering a therapeutically effective amount of a composition into an eye of the subject, wherein the composition includes any of the hydrogel compositions of the disclosure.

Disclosed herein is a non-flowable and deformable hemostatic compositions comprised of a xerogel crosslinked powdered polysaccharide dispersed within a substantially anhydrous blend of: glycerol, and polyethylene glycol (PEG), wherein the PEG and glycerol are present in a ratio ranging from higher than 1:1.3: to below 1:2.7 by weight, respectively, and wherein the powder content in the composition is above 50%, by weight. Methods of making the non-flowable compositions, and uses of the compositions in methods for treating a wound or a bleeding tissue, such as bone tissue, are further disclosed.

Disclosed herein is a non-flowable and deformable hemostatic compositions comprised of a xerogel crosslinked powdered polysaccharide dispersed within a substantially anhydrous blend of: glycerol, and polyethylene glycol (PEG), wherein the PEG and glycerol are present in a ratio ranging from higher than 1:1.3: to below 1:2.7 by weight, respectively, and wherein the powder content in the composition is above 50%, by weight. Methods of making the non-flowable compositions, and uses of the compositions in methods for treating a wound or a bleeding tissue, such as bone tissue, are further disclosed.

Disclosed herein is a non-flowable and deformable hemostatic compositions comprised of a xerogel crosslinked powdered polysaccharide dispersed within a substantially anhydrous blend of: glycerol, and polyethylene glycol (PEG), wherein the PEG and glycerol are present in a ratio ranging from higher than 1:1.3: to below 1:2.7 by weight, respectively, and wherein the powder content in the composition is above 50%, by weight. Methods of making the non-flowable compositions, and uses of the compositions in methods for treating a wound or a bleeding tissue, such as bone tissue, are further disclosed.

The present invention provides a hyaluronic acid derivative containing a disaccharide unit represented by formula (I) or formula (I) and (II), and a complex containing the hyaluronic acid derivative and a drug.

The present invention provides a hyaluronic acid derivative containing a disaccharide unit represented by formula (I) or formula (I) and (II), and a complex containing the hyaluronic acid derivative and a drug.

Compositions comprising a reverse-temperature sensitive hydrogel comprising a biopolymer such as a polysaccharide and a synthetic polymer, and a compound in an amount that reversibly inhibits respiratory enzyme complex I, and methods of using the composition, are provided.

Compositions comprising a reverse-temperature sensitive hydrogel comprising a biopolymer such as a polysaccharide and a synthetic polymer, and a compound in an amount that reversibly inhibits respiratory enzyme complex I, and methods of using the composition, are provided.